Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), licensed its ADC technology to BigHat Biosciences ...
NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced further expansion ...
Inception of the hybridoma technology for generation of mAbs 2 helped realize Ehrlich's vision with the first ADC trials underway in the 1980s. 3 - 5 The first approved ADC was gemtuzumab ozogamicin 6 ...
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza's commitment to helping customers deliver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results